Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.

Elena A ChristofidesOrlando PuentePaul NorwoodDouglas DenhamHiralal MaheshwariMichael LillestolTerence HartSamer NakhleAnurekha ChadhaDavid Fitz-PatrickDanny H SugimotoJoseph SouferDouglas YoungMark L WarrenDavid HuffmanJohn ReedHarold BaysSamir AroraBarbara RizzardiRaymond TidmanMarc RendellKimball A Johnson

Published in: Diabetes, obesity & metabolism (2024)

GL Glargine was similar to Lantus® in terms of immunogenicity, efficacy, and safety, based on the current study.

Keyphrases

glycemic control
type diabetes
open label
clinical trial
squamous cell carcinoma
metabolic syndrome
skeletal muscle
phase ii